STAAR Surgical (NASDAQ:STAA) Major Shareholder Buys $7,917,309.21 in Stock

STAAR Surgical (NASDAQ:STAA) major shareholder Broadwood Partners, L.P. acquired 497,631 shares of the company’s stock in a transaction that occurred on Friday, April 4th. The stock was bought at an average price of $15.91 per share, with a total value of $7,917,309.21. Following the transaction, the insider now directly owns 13,194,210 shares in the company, valued at $209,919,881.10. The trade was a 3.92 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Broadwood Partners, L.P. also recently made the following trade(s):

• On Monday, April 7th, Broadwood Partners, L.P. bought 138,054 shares of STAAR Surgical stock. The stock was purchased at an average cost of $15.61 per share, with a total value of $2,155,022.94.
• On Wednesday, April 2nd, Broadwood Partners, L.P. purchased 31,780 shares of STAAR Surgical stock. The shares were purchased at an average cost of $17.43 per share, for a total transaction of $553,925.40.
• On Monday, March 31st, Broadwood Partners, L.P. acquired 22,189 shares of STAAR Surgical stock. The shares were purchased at an average cost of $17.46 per share, with a total value of $387,419.94.
• On Thursday, March 27th, Broadwood Partners, L.P. bought 3,620 shares of STAAR Surgical stock. The shares were acquired at an average price of $17.48 per share, for a total transaction of $63,277.60.
• On Tuesday, March 25th, Broadwood Partners, L.P. purchased 34,296 shares of STAAR Surgical stock. The shares were acquired at an average price of $17.44 per share, with a total value of $598,122.24.
• On Thursday, March 20th, Broadwood Partners, L.P. acquired 108,720 shares of STAAR Surgical stock. The stock was acquired at an average price of $17.96 per share, for a total transaction of $1,952,611.20.
• On Tuesday, March 18th, Broadwood Partners, L.P. bought 93,124 shares of STAAR Surgical stock. The shares were acquired at an average cost of $17.54 per share, with a total value of $1,633,394.96.
• On Monday, March 3rd, Broadwood Partners, L.P. purchased 249,503 shares of STAAR Surgical stock. The stock was bought at an average price of $16.64 per share, for a total transaction of $4,151,729.92.
• On Thursday, February 27th, Broadwood Partners, L.P. acquired 259,316 shares of STAAR Surgical stock. The stock was bought at an average price of $17.05 per share, with a total value of $4,421,337.80.
• On Friday, February 14th, Broadwood Partners, L.P. bought 36,532 shares of STAAR Surgical stock. The shares were bought at an average price of $15.49 per share, for a total transaction of $565,880.68.

STAAR Surgical Price Performance

STAA opened at $15.09 on Wednesday. The company has a market capitalization of $744.31 million, a price-to-earnings ratio of -36.80 and a beta of 0.75. The business’s 50-day moving average price is $18.27 and its two-hundred day moving average price is $24.38. STAAR Surgical has a 1 year low of $13.50 and a 1 year high of $52.68.

Institutional Investors Weigh In On STAAR Surgical

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Quarry LP acquired a new position in STAAR Surgical during the 3rd quarter worth approximately $50,000. KLP Kapitalforvaltning AS bought a new stake in shares of STAAR Surgical in the fourth quarter worth $180,000. GAMMA Investing LLC boosted its holdings in STAAR Surgical by 4,086.0% during the first quarter. GAMMA Investing LLC now owns 14,651 shares of the medical instruments supplier’s stock worth $258,000 after purchasing an additional 14,301 shares during the last quarter. Bridgefront Capital LLC grew its position in STAAR Surgical by 27.2% in the fourth quarter. Bridgefront Capital LLC now owns 10,792 shares of the medical instruments supplier’s stock valued at $262,000 after purchasing an additional 2,306 shares in the last quarter. Finally, FMR LLC increased its stake in STAAR Surgical by 79.3% in the 3rd quarter. FMR LLC now owns 7,092 shares of the medical instruments supplier’s stock valued at $263,000 after buying an additional 3,136 shares during the last quarter. Institutional investors and hedge funds own 96.70% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on STAA. Stephens reiterated an “equal weight” rating and issued a $17.00 price target on shares of STAAR Surgical in a research report on Tuesday, March 18th. StockNews.com lowered shares of STAAR Surgical from a “hold” rating to a “sell” rating in a report on Thursday, February 13th. Needham & Company LLC reissued a “hold” rating on shares of STAAR Surgical in a report on Thursday, February 27th. William Blair downgraded STAAR Surgical from an “outperform” rating to a “market perform” rating in a research note on Wednesday, February 12th. Finally, Piper Sandler reduced their target price on STAAR Surgical from $40.00 to $16.00 and set a “neutral” rating on the stock in a report on Wednesday, February 12th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $25.29.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.